Literature DB >> 22954464

Adoption in China of Clinical Practice Guidelines for hypertension using Traditional Chinese Medical approaches: a literature review based on clinical studies.

Nannan Shi1, Xuejie Han, Wenya Yu, Liying Wang, Aiping Lu.   

Abstract

BACKGROUND: Increasing Clinical Practice Guidelines (CPGs) of Traditional Chinese Medicine (TCM) have been developed in China, and it is not clear about the real application in the clinical studies. This study aimed to analyze the adoption of CPGs for hypertension using TCM therapy by investigating the clinical research literature on representative CPGs for TCM in China.
METHODS: All CPGs on TCM for hypertension were collected and investigated from all of the clinical research literature published in China from January 2005 to December 2010. Ten (10) CPGs on TCM for hypertension were searched and analyzed, collecting data about the issuing organization, date of publication, classification, characteristics, contents, and citation rates.
RESULTS: By the end of December 2008, 10 CPGs on TCM for hypertension were found. Of these guidelines, one was a Chinese national standard, one was a local authority standard, two were professional administration standard, and six were academic association standards. Furthermore, four were compiled under the title of hypertension based on TCM syndrome differentiation and six were only compiled under the title of a TCM syndrome. Of all the research articles (n=695), TCM CPGs were cited in 417 articles (60%). TCM CPGs on hypertension were commonly used as standards for diagnosis and/or outcome measurements. Three hundred and seventy-nine (379) clinical research articles were unclear or inconsistent in their adoption of TCM CPG, accounting for 55% of all clinical articles. Seven (7) categories of inconsistent or unclear citations of TCM CPG were identified, and the total amount of occurrences of seven categories on inconsistent citation was 572.
CONCLUSIONS: About 60% publications cited the CPGs for their clinical research, and most of them cited in an inconsistent and unclear way. According to the result, better training of TCM practitioners and improvement of CPG development and adoption are needed.

Entities:  

Mesh:

Year:  2012        PMID: 22954464     DOI: 10.1089/acm.2011.0776

Source DB:  PubMed          Journal:  J Altern Complement Med        ISSN: 1075-5535            Impact factor:   2.579


  12 in total

1.  Designing clinical studies that take into account traditional East Asian medicine's systems and methods - with focus on pattern identification.

Authors:  Terje Alraek
Journal:  Chin J Integr Med       Date:  2014-05-02       Impact factor: 1.978

2.  Editorial: Combination Therapy of Vascular Diseases and Fangjiomics: When West Meets East in the Era of Phenomics.

Authors:  Zhong Wang; Dayue Darrel Duan; Yong-Yan Wang
Journal:  Curr Vasc Pharmacol       Date:  2015       Impact factor: 2.719

Review 3.  Appraisal of the Quality and Contents of Clinical Practice Guidelines for Hypertension Management in Chinese Medicine: A Systematic Review.

Authors:  Ya Yuwen; Xue-Jie Han; Wei-Liang Weng; Xue-Yao Zhao; Yu-Qi Liu; Wei-Qiang Li; Da-Sheng Liu; Yan-Ping Wang; Ai-Ping Lu
Journal:  Chin J Integr Med       Date:  2016-12-09       Impact factor: 1.978

4.  Autophagy interplays with apoptosis and cell cycle regulation in the growth inhibiting effect of Trisenox in HEP-2, a laryngeal squamous cancer.

Authors:  Débora Lima Pereira; Ana Carolina Dos Santos Ferreira; Giselle Pinto de Faria; Jolie Kiemlian Kwee
Journal:  Pathol Oncol Res       Date:  2014-05-18       Impact factor: 3.201

5.  Chinese herbal therapy and Western drug use, belief and adherence for hypertension management in the rural areas of Heilongjiang province, China.

Authors:  Xia Li; Mingkai Peng; Yuan Li; Zheng Kang; Yanhua Hao; Hong Sun; Lijun Gao; Mingli Jiao; Qunhong Wu; Hude Quan
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

Review 6.  Use of Kampo diagnosis in randomized controlled trials of Kampo products in Japan: a systematic review.

Authors:  Yoshiharu Motoo; Ichiro Arai; Kiichiro Tsutani
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

7.  A national survey of Chinese medicine doctors and clinical practice guidelines in China.

Authors:  Mengyu Liu; Chi Zhang; Qinglin Zha; Wei Yang; Ya Yuwen; Linda Zhong; Zhaoxiang Bian; Xuejie Han; Aiping Lu
Journal:  BMC Complement Altern Med       Date:  2017-09-06       Impact factor: 3.659

8.  Metabonomics study of essential hypertension and its chinese medicine subtypes by using gas chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy.

Authors:  Yunlun Li; Lei Nie; Haiqiang Jiang; Jiamao Lin; Honglei Zhou; Jun Xie; Zhengjun Qu; Dongmei Qi; Yunhui Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-25       Impact factor: 2.629

9.  Chinese patent medicine tongxinluo capsule for hypertension: a systematic review of randomised controlled trials.

Authors:  Jie Wang; Xingjiang Xiong; Wei Liu
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-17       Impact factor: 2.629

10.  Effects of Lifestyle Modification on Telomerase Gene Expression in Hypertensive Patients: A Pilot Trial of Stress Reduction and Health Education Programs in African Americans.

Authors:  Shanthi Duraimani; Robert H Schneider; Otelio S Randall; Sanford I Nidich; Shichen Xu; Muluemebet Ketete; Maxwell A Rainforth; Carolyn Gaylord-King; John W Salerno; John Fagan
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.